Homology-based repair induced by CRISPR-Cas nucleases in mammalian embryo genome editing.
10.1007/s13238-021-00838-7
- Author:
Xiya ZHANG
1
;
Tao LI
1
;
Jianping OU
2
;
Junjiu HUANG
3
;
Puping LIANG
4
Author Information
1. Center for Reproductive Medicine, the Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, 510630, China.
2. Center for Reproductive Medicine, the Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, 510630, China. oujp3@mail.sysu.edu.cn.
3. MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, 510275, China. hjunjiu@mail.sysu.edu.cn.
4. MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, 510275, China. liangpp5@mail.sysu.edu.cn.
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords:
disease modeling;
embryo;
genome editing;
homology-based repair (HBR);
precision medicine
- MeSH:
Animals;
CRISPR-Cas Systems/genetics*;
DNA/genetics*;
Embryo, Mammalian/metabolism*;
Endonucleases/metabolism*;
Gene Editing;
Mammals/metabolism*
- From:
Protein & Cell
2022;13(5):316-335
- CountryChina
- Language:English
-
Abstract:
Recent advances in genome editing, especially CRISPR-Cas nucleases, have revolutionized both laboratory research and clinical therapeutics. CRISPR-Cas nucleases, together with the DNA damage repair pathway in cells, enable both genetic diversification by classical non-homologous end joining (c-NHEJ) and precise genome modification by homology-based repair (HBR). Genome editing in zygotes is a convenient way to edit the germline, paving the way for animal disease model generation, as well as human embryo genome editing therapy for some life-threatening and incurable diseases. HBR efficiency is highly dependent on the DNA donor that is utilized as a repair template. Here, we review recent progress in improving CRISPR-Cas nuclease-induced HBR in mammalian embryos by designing a suitable DNA donor. Moreover, we want to provide a guide for producing animal disease models and correcting genetic mutations through CRISPR-Cas nuclease-induced HBR in mammalian embryos. Finally, we discuss recent developments in precise genome-modification technology based on the CRISPR-Cas system.
